Literature DB >> 1934337

Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure.

M Ontkean1, R Gay, B Greenberg.   

Abstract

Abnormalities in vasomotor tone, including enhanced vasoconstriction at rest and diminished vasodilation in response to various stimuli, develop as a consequence of chronic heart failure. This study was undertaken to evaluate whether a specific local mechanism, namely endothelium-derived relaxing factor (EDRF) activity, might be impaired in an experimental model of chronic heart failure. Segments of thoracic aorta (TA) and pulmonary artery (PA) were isolated from a group of rats that had hemodynamic evidence of heart failure 10 weeks after ligation of the left coronary artery (n = 25) and from a group of sham-operated control rats (n = 18). Both endothelium-dependent and endothelium-independent vascular responses were assessed by exposing arterial segments to increasing concentrations of agonists. All studies were performed in the presence of 10 microM indomethacin to avoid the influence of vasoactive prostanoids. The dose-response curve for EDRF-mediated relaxation to acetylcholine was shifted rightward in rats with heart failure, and the concentrations of acetylcholine required to achieve 50% maximal relaxation (EC50) were increased compared with those of control rats in both TA and PA segments. Additionally, the dose-response curve for relaxation to ADP was shifted rightward with significantly increased EC50 in PA segments from rats with heart failure. In contrast, EDRF-mediated relaxation to the calcium ionophore A23187 was similar in the groups. Endothelium-independent relaxation to nitroglycerin was slightly increased in TA but not PA segments in the heart-failure group. Basal EDRF activity, as assessed by the increase in force after exposure to hemoglobin, was diminished in PA segments from rats with heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934337     DOI: 10.1161/01.res.69.4.1088

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  23 in total

Review 1.  Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure.

Authors:  Stuart D Katz; Haoyi Zheng
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

2.  Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction.

Authors:  Daphne Merkus; Birgit Houweling; Vincent J de Beer; Zaida Everon; Dirk J Duncker
Journal:  J Physiol       Date:  2007-02-08       Impact factor: 5.182

3.  Endothelial control of lower limb blood flow in chronic heart failure.

Authors:  D C Lindsay; D R Holdright; D Clarke; I S Anand; P A Poole-Wilson; P Collins
Journal:  Heart       Date:  1996-05       Impact factor: 5.994

4.  Pulmonary vascular mechanical consequences of ischemic heart failure and implications for right ventricular function.

Authors:  Jennifer L Philip; Thomas M Murphy; David A Schreier; Sydney Stevens; Diana M Tabima; Margie Albrecht; Andrea L Frump; Timothy A Hacker; Tim Lahm; Naomi C Chesler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-15       Impact factor: 4.733

Review 5.  Soluble guanylate cyclase: a potential therapeutic target for heart failure.

Authors:  Mihai Gheorghiade; Catherine N Marti; Hani N Sabbah; Lothar Roessig; Stephen J Greene; Michael Böhm; John C Burnett; Umberto Campia; John G F Cleland; Sean P Collins; Gregg C Fonarow; Phillip D Levy; Marco Metra; Bertram Pitt; Piotr Ponikowski; Naoki Sato; Adriaan A Voors; Johannes-Peter Stasch; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 6.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

Review 7.  The treatment of heart failure--what next?

Authors:  R H Davies; D J Sheridan
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 8.  Cardiorenal syndrome: pathophysiology and potential targets for clinical management.

Authors:  Parta Hatamizadeh; Gregg C Fonarow; Matthew J Budoff; Sirous Darabian; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

Review 9.  The TNF-α/sphingosine-1-phosphate signaling axis drives myogenic responsiveness in heart failure.

Authors:  Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Vasc Res       Date:  2013-04-16       Impact factor: 1.934

10.  Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase.

Authors:  J F Arnal; L Warin; J B Michel
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.